Management and Outcome of XXXX -Induced @entity882 in Pregnancy: A Systematic Review.

@entity1 @entity3152 @entity882 @entity2067 @entity20806 @entity532 @entity6950 @entity1468 @entity715
OBJECTIVE: Safety and efficacy of therapeutic agents used for @entity6950 -induced @entity882 are not established in pregnancy. METHODS: MEDLINE database was searched in November 2014 to identify all @entity1 who received therapy for HIT during pregnancy. RESULTS: A total of 12 @entity1 with the median age of 28 years (range 21-39) were diagnosed with HIT at the median gestational age of 20 weeks (range 5-34). Clinical probability (4T) score for HIT was high (50%) or intermediate (50%) and associated with @entity715 in 50%. @entity1 were initially managed with lepirudin (33%), @entity20806 (25%), danaparoid (25%) or fondaparinux (17%) and ultimately bridged to @entity2067 antagonist or maintained on lepirudin. All @entity1 had resolution of HIT. Complications included therapeutic abortion prior to valve replacement for valve @entity715 (8%), @entity3152 (18%) and @entity1468 (8%). Except for one instance of hypoplastic lung related to @entity3152 , none of the other newborns had any complications during delivery. CONCLUSION: Confirmed cases of HIT in pregnant @entity1 appear to be rare. Within the limits of retrospective analysis, the use of @entity20806 , danaparoid, fondaparinux and lepirudin may be effective in preventing the @entity715 complications of HIT in pregnancy. The effect of HIT or its therapy on @entity532 cannot be determined based on this study since many of the @entity532 are common in otherwise healthy pregnancies. Although this study did not identify any fetal teratogenicity except hypoplastic lung related to @entity3152 , small number of cases treated with various therapies precludes any definite conclusion.
